Syntis Bio Launches in Effort to Challenge GLP-1s in Lucrative Weight Loss Market

Endoscopy procedure/iStock, Marina113

Pictured: 3D illustration of an intestine undergoing an endoscopy procedure/iStock, Marina113

Boston-based biotech Syntis Bio launched on Tuesday with the goal of advancing alternatives to GLP-1 receptor agonists for the treatment of obesity and other metabolic and rare conditions.

Syntis’ lead program is SYNT-101,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks